Patients with hematologic malignancies often have a complex array of medical issues. Our Hematologic Malignancies Service brings together a team of specialists to provide patients with individualized treatment plans without duplicating services. Patients are evaluated by:

  • Medical oncologists/hematologists
  • Specialized nurses, nurse practitioners, and research nurses
  • Radiation oncologists
  • Pathologists
  • Nutritionists
  • Social workers

The team offers a comprehensive range of diagnostic and treatment services designed to provide patients with the most effective care possible. Services include:

  • On-site specialized diagnostic and support services, including hematopathology, molecular diagnosis, immunophenotyping, special cell component therapy and pheresis, and infectious disease specialists
  • Integrated programs with the Blood and Marrow Transplant Program
  • Second opinions
  • New therapies

We also treat benign hematology – bleeding disorders, red cell disorders, platelet abnormalities and white cell disorders.

A major goal of Hematologic Malignancies Service is to develop new curative approaches for leukemias, lymphomas and myelomas. For example:

  • We offer a number of NCI-funded Phase I and II innovative clinical trials of new drugs and novel drug combinations for patients with newly diagnosed or relapsed and/or refractory leukemias and myelodysplasia.
  • We use novel immunotherapy approaches to treat Chronic Myelogenous Leukemia (CML), lymphoma and multiple myeloma.
  • We offer new molecularly-targeted drugs for multiple myeloma.